SCHEDULE 13G/A: Cormorant Asset Management Discloses 13.36% Corbus Stake

Cormorant Asset Management and Bihua Chen have disclosed a 13.36% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. common stock.

Summary

• Cormorant Asset Management, LP and Bihua Chen collectively beneficially own 2,344,971 shares of Corbus Pharmaceuticals Holdings, Inc. common stock.
• This ownership represents 13.36% of the issuer's outstanding common stock.
• The percentage is calculated based on 17,553,037 shares outstanding as of November 7, 2025, as reported in the issuer's Form 10-Q.
• Both reporting persons hold shared voting power and shared dispositive power over all 2,344,971 shares.
• Cormorant Asset Management serves as the investment manager for Cormorant Global Healthcare Master Fund, LP, which beneficially owns these shares.
• Bihua Chen is the managing member of Cormorant Global Healthcare GP, LLC (general partner of the Master Fund) and the general partner of Cormorant Asset Management.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a reputable asset manager like Cormorant Asset Management is generally viewed positively by the market, indicating confidence in the company's prospects.

Positives

• A significant beneficial ownership stake (13.36%) by a specialized healthcare investment firm like Cormorant Asset Management can signal strong institutional confidence in Corbus Pharmaceuticals Holdings, Inc.'s future prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, suggesting a long-term investment perspective.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Management Comments

• The securities were acquired and are held in the ordinary course of business.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Corbus Pharmaceuticals Holdings, Inc.
• The acquisition and holding of securities are not connected with or as a participant in any transaction having the purpose or effect of influencing control, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

A significant institutional stake in a biotechnology or pharmaceutical company like Corbus Pharmaceuticals Holdings, Inc. by a specialized healthcare investor often indicates a belief in the company's drug pipeline, strategic direction, or long-term value proposition within the competitive healthcare sector.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The disclosure of a substantial institutional stake may instill confidence among existing shareholders and attract new investors, potentially influencing stock price positively.
• Company Management: A large institutional holder, even if not seeking control, represents a significant voice and can influence strategic decisions through engagement.

Key Dates

Recommendation

The disclosure of a 13.36% beneficial ownership by Cormorant Asset Management, a prominent healthcare-focused investment firm, signals strong institutional conviction in Corbus Pharmaceuticals Holdings, Inc. This significant stake, held for investment purposes rather than control, suggests a positive long-term outlook for the company's value and prospects, making it an attractive 'buy' signal for investors.

Keywords

Corbus Pharmaceuticals, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Healthcare Investment